Flutamide
Brand names: Eulexin · Active ingredient: Flutamide
In short: Eulexin® capsules are indicated for use in combination with LHRH-agonists for the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate. Treatment with Eulexin® capsules and the goserelin acetate implant should start eight weeks prior to initiating radiation the
What is Flutamide used for?
Eulexin® capsules are indicated for use in combination with LHRH-agonists for the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate.
Treatment with Eulexin® capsules and the goserelin acetate implant should start eight weeks prior to initiating radiation therapy and continue during radiation therapy.
To achieve benefit from treatment, Eulexin® capsules should be initiated with the LHRH-agonist and continued until progression.
⚠ Boxed warning (FDA's strongest warning)
There have been postmarketing reports of hospitalization and rarely death due to liver failure in patients taking Eulexin® . Evidence of hepatic injury included elevated serum transaminase levels, jaundice, hepatic encephalopathy and death related to acute hepatic failure. The hepatic injury was reversible after discontinuation of therapy in some patients. Approximately half of the reported cases occurred within the initial 3 months of treatment with Eulexin
®
.
Serum transaminase levels should be measured prior to starting treatment with Eulexin®. Eulexin® is not recommended in patients whose ALT values exceed twice the upper limit of normal. Serum transaminase levels should then be measured monthly for the first 4 months of therapy, and periodically thereafter. Liver function tests also should be obtained at the first signs and symptoms suggestive of liver dysfunction, e.g., nausea, vomiting, abdominal pain, fatigue, anorexia, "flu-like" symptoms, hyperbilirubinuria, jaundice or right upper quadrant tenderness. If at any time, a patient has jaundice, or their ALT rises above 2 times the upper limit of normal, Eulexin® should be immediately discontinued with close follow-up of liver function tests until resolution.
SEE BOXED WARNINGS
Eulexin® capsules are for use only in men. This product has no indication for women and should not be used in this population, particularly for nonserious or nonlife-threatening conditions.
Eulexin® may cause fetal harm when administered to a pregnant woman .
One metabolite of Eulexin® is 4-nitro-3-fluoro-methylaniline. …
Flutamide dosage
The recommended dosage is 2 capsules 3 times a day at 8 hour intervals for a total daily dose of 750 mg.
How to take Flutamide — instructions & advice from the label
Important information for patients taking Eulexin® capsules.
Read this information carefully each time your prescription is refilled because there may be new information available. This summary does not tell you everything you need to know about Eulexin® therapy. Your doctor is the best source of information about your treatment. Ask your doctor about questions you have.
What is Eulexin® therapy?
Eulexin
®
capsules, in combination with other therapies, is a treatment option for men with some types of prostate cancer.
Prostate cancer results from the abnormal growth of prostate cells. Medical scientists do not know exactly what causes the abnormal cells, but age, environment, and genetics are important factors. Male hormones ("androgens") cause the cancer to grow. The cancer growth can be slowed down by blocking the effect of androgens.
The Eulexin
®
product is used together with an injection called "LHRH agonist," as a combined treatment called "total androgen blockade." The goal of this treatment is to reduce androgen levels and to block the effect of androgen on the tumor. The LHRH agonist reduces androgen levels. Eulexin
®
therapy blocks the effect of androgen on the tumor. …
Warnings & precautions
Do not take this medicine if: Eulexin® capsules are contraindicated in patients who are hypersensitive to Eulexin® or any component of this preparation.
Eulexin® capsules are contraindicated in patients with severe hepatic impairment (baseline hepatic enzymes should be evaluated prior to treatment).
In clinical trials, gynecomastia occurred in 9% of patients receiving Eulexin® together with medical castration.
Patients should be informed that Eulexin® capsules and the drug used for medical castration should be administered concomitantly, and that they should not interrupt their dosing or stop taking these medications without consulting their physician.
Regular assessment of serum Prostate Specific Antigen (PSA) may be helpful in monitoring the patient's response. If PSA levels rise significantly and consistently during Eulexin® therapy the patient should be evaluated for clinical progression. For patients who have objective progression of disease together with an elevated PSA, a treatment period free of antiandrogen while continuing the LHRH analogue may be considered.
Increases in prothrombin time have been noted in patients receiving long-term warfarin therapy after Eulexin® was initiated. Therefore close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when Eulexin® capsules are administered concomitantly with warfarin.
In a 1 year dietary study in male rats, interstitial cell adenomas of the testes were present in 49% to 75% of all treated rats (daily doses of 10, 30, and 50 mg/kg/day were administered). These produced plasma Cmax values that are 1, 2, 3, and 4 fold respectively, those associated with therapeutic doses in humans. In male rats similarly dosed for 1 year, tumors were still present after 1 year of a drug-free period, but the incidences were 43% to 47%. …
Flutamide side effects
Treatment with Eulexin® capsules and the goserelin acetate implant did not add substantially to the toxicity of radiation treatment alone. The following adverse experiences were reported during a multicenter clinical trial comparing Eulexin
®
+ goserelin acetate implant + radiation versus radiation alone. The most frequently reported (greater than 5%) adverse experiences are listed below:
(n=231) Goserelin Acetate Implant + Eulexin®
+ Radiation | (n=235) Radiation Only
% All | % All
Rectum/Large Bowel | 80 | 76
Bladder | 58 | 60
Skin | 37 | 37
(n=231) Goserelin Acetate Implant + Eulexin®
+ Radiation | (n=235) Radiation Only
% All | % All
Diarrhea | 36 | 40
Cystitis | 16 | 16
Rectal Bleeding | 14 | 20
Proctitis | 8 | 8
Hematuria | 7 | 12
Additional adverse event data were collected for the combination therapy with radiation group over both the hormonal treatment and hormonal treatment plus radiation phases of the study. Adverse experiences occurring in more than 5% of patients in this group, over both parts of the study, were hot flashes (46%), diarrhea (40%), nausea (9%), and skin rash (8%).
The following adverse experiences were reported during a multicenter clinical trial comparing Eulexin
®
+ LHRH agonist versus placebo + LHRH agonist.
The most frequently reported (greater than 5%) adverse experiences during treatment with Eulexin
®
capsules in combination with an LHRH agonist are listed in the table below. …
About this medicine
Eulexin® capsules contain flutamide, an acetanilid, nonsteroidal, orally active antiandrogen having the chemical name, α,α,α-trifluoro-2-methyl-4'-nitro-m-propionotoluidide.
Each capsule contains 125 mg flutamide. The compound is a buff to yellow powder with a molecular weight of 276.22 and the following structural formula:
C11H11F3N2O3
In addition, each capsule contains the following inactive ingredients: corn starch, lactose monohydrate, magnesium stearate, povidone, and sodium lauryl sulfate. Gelatin capsule shells may contain gelatin, silicon dioxide, sodium lauryl sulfate, titanium dioxide, FDA/E172 Red Iron Oxide, FDA/E172 Yellow Iron Oxide, and black ink containing pharmaceutical glaze (modified) in SD-45, synthetic black iron oxide, N-butyl alcohol, SDA-3A alcohol, FD&C Blue No.2 Aluminum Lake, FD&C Red No.40 Aluminum Lake, FD&C Blue No.1 Aluminum Lake, and D&C Yellow No.10 Aluminum Lake.
How it works: In animal studies, flutamide demonstrates potent antiandrogenic effects. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 0a905e25-42b6-4937-a689-f01a8f22e644. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate